Stock comparison
Moderna, Inc. is 4.5x more valuable than Arcellx, Inc. by market capitalization ($30.38 B vs $6.73 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Moderna, Inc. is 4.5x more valuable than Arcellx, Inc. by market capitalization ($30.38 B vs $6.73 B).
Market value leader
MRNA
Moderna, Inc. is 4.5x more valuable than Arcellx, Inc. by market capitalization ($30.38 B vs $6.73 B).
Revenue leader
MRNA
ACLX: $22.29M vs MRNA: $1.94B.
Profit leader
ACLX
ACLX: -$228.93M vs MRNA: -$2.82B.
Margin leader
MRNA
ACLX: -1027.3% vs MRNA: -145.2% net margin.
| Metric | ACLX | MRNA |
|---|---|---|
| Market cap | $6.73 B | $30.38 B |
| US-listed rank | #1197 | #461 |
| Revenue (latest FY) | $22.29M | $1.94B |
| Net income (latest FY) | -$228.93M | -$2.82B |
| Net margin | -1027.3% | -145.2% |
| P/E (trailing FY) | - | - |
| SEC filings | 448 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Moderna, Inc. is 4.5x more valuable than Arcellx, Inc. by market capitalization ($30.38 B vs $6.73 B).
In their latest fiscal years, Arcellx, Inc. reported $22.29M in revenue while Moderna, Inc. reported $1.94B.
Full pages: Arcellx, Inc. and Moderna, Inc., or browse the full rankings.